{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T19:00:11Z","timestamp":1778266811475,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Systemic sclerosis (SSc) is considered by many to be one of the most severe autoimmune rheumatic diseases with lower prevalence observed in Northern Europe. No previous studies on the prevalence of SSc in Latvia have been conducted and the aim was to study the demographic and clinical data of patients with SSc in northeastern Europe country.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study was conducted in two main Latvian hospitals for adults and includes patients with SSc who were consulted between 2016 and 2021.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>During the study period, 159 patients with SSc were consulted. The point prevalence on 1 January 2021 was 84.0 per million. Female to male ratio was 4.67:1, and highest gender ratio was observed in the age group 70\u201379-year (6.75:1). Antinuclear antibodies were present in 82.58% of patients, without gender difference. Centromere pattern was more frequently observed in females (40.19% vs. 19.04%), in contrast to speckled pattern (50.98% vs. 57.14%). At disease onset females tended to be younger (46.51\u2009\u00b1\u200913.52) than males (50.5\u2009\u00b1\u200916.64). Males had more diffuse cutaneous subtype, interstitial lung disease, pulmonary hypertension and esophageal dysmotility. More than half of patients received treatment with glucocorticoids at any point of the disease (68.31%), without gender difference.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Systemic sclerosis is less common in Latvia than in other countries and regions. Due to its location, the data from Latvia are consistent with a north-south gradient in Europe. Gender ratio differences persisted in older age groups as well. Antinuclear antibodies presence did not differ between genders, but in female\u2019s centromere pattern was much more likely to be present. Males had more severe disease course, but in both genders more than half of patients received treatment with GCs at any point of the disease.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-024-03355-y","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T10:03:16Z","timestamp":1727690596000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prevalence and gender - specific analysis of a systemic sclerosis cohort in Latvia"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2127-2948","authenticated-orcid":false,"given":"Kristine","family":"Ivanova","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Ribakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mihailova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelina","family":"Mozeitovica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anda","family":"Kadisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julija","family":"Zepa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktorija","family":"Kenina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalja","family":"Kurjane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inita","family":"Bulina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"3355_CR1","doi-asserted-by":"publisher","unstructured":"Rodnan GP, Benedek TG. An historical account of the study of progressive systemic sclerosis (diffuse scleroderma). Ann Intern Med. 1962;57(2_Part_1):305. https:\/\/doi.org\/10.7326\/0003-4819-57-2-305.","DOI":"10.7326\/0003-4819-57-2-305"},{"key":"3355_CR2","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","year":"1980","unstructured":"Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23:581\u201390.","journal-title":"Arthritis Rheum"},{"key":"3355_CR3","first-page":"771","volume-title":"McKee\u2019s pathology of the skin: with clinical correlations","author":"E Calonje","year":"2020","unstructured":"Calonje E, Brenn T, Lazar A, Billings SD. Chapter 17. McKee\u2019s pathology of the skin: with clinical correlations. Scotland: Edinburgh; 2020. pp. 771\u2013825."},{"issue":"10","key":"3355_CR4","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1002\/acr.24411","volume":"73","author":"EY Yen","year":"2020","unstructured":"Yen EY, Singh DR, Singh RR. Trends in systemic sclerosis mortality over forty-eight years, 1968-2015: a US population-based study. Arthritis Care Res (Hoboken). 2020;73(10):1502\u201310. https:\/\/doi.org\/10.1002\/acr.24411.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3355_CR5","unstructured":"EULAR textbook on systemic sclerosis. 1st ed. London, England; 2013. pp. 3\u201315."},{"issue":"1","key":"3355_CR6","doi-asserted-by":"publisher","first-page":"e37","DOI":"10.1111\/bjd.15838","volume":"178","author":"GW Kang","year":"2017","unstructured":"Kang GW, Jung KH, Lee YS, Kim HJ, Yoon DY, Lee SH, et al. Incidence, prevalence, mortality and causes of death in systemic sclerosis in Korea: a nationwide population-based study. Br J Dermatol. 2017;178(1):e37\u20139. https:\/\/doi.org\/10.1111\/bjd.15838.","journal-title":"Br J Dermatol"},{"issue":"1","key":"3355_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/2397198318819908","volume":"5","author":"P Air\u00f2","year":"2019","unstructured":"Air\u00f2 P, Regola F, Lazzaroni M-G, Tincani A, Inverardi F, Fenini MG, et al. Incidence and prevalence of systemic sclerosis in Valcamonica, Italy, during an 18-year period. J Scleroderma Relat Disord. 2019;5(1):51\u20136. https:\/\/doi.org\/10.1177\/2397198318819908.","journal-title":"J Scleroderma Relat Disord"},{"issue":"4","key":"3355_CR8","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3899\/jrheum.111106","volume":"39","author":"DE Furst","year":"2012","unstructured":"Furst DE, Fernandes AW, Iorga SR, Greth W, Bancroft T. Epidemiology of systemic sclerosis in a large US managed care population. J Rheumatol. 2012;39(4):784\u20136. https:\/\/doi.org\/10.3899\/jrheum.111106.","journal-title":"J Rheumatol"},{"issue":"4","key":"3355_CR9","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.semarthrit.2007.05.003","volume":"37","author":"H Chifflot","year":"2008","unstructured":"Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum. 2008;37(4):223\u201335. https:\/\/doi.org\/10.1016\/j.semarthrit.2007.05.003.","journal-title":"Semin Arthritis Rheum"},{"key":"3355_CR10","volume-title":"Epidemiology of the rheumatic diseases","author":"AJ Silman","year":"2002","unstructured":"Silman AJ. In: Silman AJ, Hochberg MC, editors. Epidemiology of the rheumatic diseases. 2nd ed. London, England: Oxford University Press; 2002.","edition":"2"},{"issue":"3","key":"3355_CR11","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1002\/art.1780400309","volume":"40","author":"VD Steen","year":"1997","unstructured":"Steen VD, Oddis CV, Conte CG, Janoski J, Casterline GZ, Medsger TA. Incidence of systemic sclerosis in Allegheny County, Pennsylvania. A twenty-year study of hospital-diagnosed cases, 1963-1982. Arthritis Rheum. 1997;40(3):441\u20135. https:\/\/doi.org\/10.1002\/art.1780400309.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"3355_CR12","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s10067-005-0177-y","volume":"25","author":"CT Derk","year":"2006","unstructured":"Derk CT, Artlett CM, Jimenez SA. Morbidity and mortality of patients diagnosed with systemic sclerosis after the age of 75: a nested case-control study. Clin Rheumatol. 2006;25(6):831\u20134. https:\/\/doi.org\/10.1007\/s10067-005-0177-y.","journal-title":"Clin Rheumatol"},{"key":"3355_CR13","doi-asserted-by":"publisher","unstructured":"Hughes M, Pauling JD, Armstrong-James L, Denton CP, Galdas P, Flurey C. Gender-related differences in systemic sclerosis. Autoimmun Rev. 2020;19(4):102494. https:\/\/doi.org\/10.1016\/j.autrev.2020.102494","DOI":"10.1016\/j.autrev.2020.102494"},{"key":"3355_CR14","doi-asserted-by":"publisher","unstructured":"Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative: ACR\/EULAR classification criteria for SSc. Arthritis Rheum. 2013;65(11):2737\u201347. https:\/\/doi.org\/10.1002\/art.38098","DOI":"10.1002\/art.38098"},{"key":"3355_CR15","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1136\/annrheumdis-2016-209768","volume":"76","author":"G Valentini","year":"2017","unstructured":"Valentini G, Iudici M, Walker UA. The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity indexAnnals. Rheumatic Dis. 2017;76:270\u20136.","journal-title":"Rheumatic Dis"},{"key":"3355_CR16","unstructured":"Latvia population. Live \u2014 Countrymeters. 2023. https:\/\/countrymeters.info\/en\/Latvia. Accessed 31 Jan 2023."},{"key":"3355_CR17","unstructured":"Wikipedia contributors. Demographics of Latvia. Wikipedia, The Free Encyclopedia. 2023. https:\/\/en.wikipedia.org\/w\/index.php?title=Demographics_of_Latvia&oldid=1136676806. Accessed 31 Jan 2023."},{"issue":"6","key":"3355_CR18","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3109\/03009749709065713","volume":"26","author":"I Valter","year":"1997","unstructured":"Valter I, Saretok S, Maricq HR. Prevalence of scleroderma spectrum disorders in the general population of Estonia. Scand J Rheumatol. 1997;26(6):419\u201325. https:\/\/doi.org\/10.3109\/03009749709065713.","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"3355_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.5114\/reum.2019.87619","volume":"57","author":"P Sobolewski","year":"2019","unstructured":"Sobolewski P, Ma\u015bli\u0144ska M, Wieczorek M. Systemic sclerosis - multidisciplinary disease: clinical features and treatment. Reumatologia. 2019;57(4):221\u201333. https:\/\/doi.org\/10.5114\/reum.2019.87619.","journal-title":"Reumatologia"},{"issue":"9","key":"3355_CR20","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1093\/rheumatology\/kes076","volume":"51","author":"A-M Hoffmann-Vold","year":"2012","unstructured":"Hoffmann-Vold A-M, Midtvedt \u00d8, Molberg \u00d8, Garen T, Gran JT. Prevalence of systemic sclerosis in south-east Norway. Rheumatology (Oxford). 2012;51(9):1600\u20135. https:\/\/doi.org\/10.1093\/rheumatology\/kes076.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"3355_CR21","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1136\/annrheumdis-2013-203618","volume":"73","author":"K Andr\u00e9asson","year":"2013","unstructured":"Andr\u00e9asson K, Saxne T, Bergknut C, Hesselstrand R, Englund M. Prevalence and incidence of systemic sclerosis in southern Sweden: population-based data with case ascertainment using the 1980 ARA criteria and the proposed ACR-EULAR classification criteria. Ann Rheum Dis. 2013;73(10):1788\u201392. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203618.","journal-title":"Ann Rheum Dis"},{"key":"3355_CR22","doi-asserted-by":"publisher","first-page":"257","DOI":"10.2147\/CLEP.S191418","volume":"11","author":"A Bergamasco","year":"2019","unstructured":"Bergamasco A, Hartmann N, Wallace L, Verpillat P. Epidemiology of systemic sclerosis and systemic sclerosis-associated interstitial lung disease. Clin Epidemiol. 2019;11:257\u201373. https:\/\/doi.org\/10.2147\/CLEP.S191418.","journal-title":"Clin Epidemiol"},{"key":"3355_CR23","doi-asserted-by":"publisher","unstructured":"Westerlind H, Bairkdar M, Gunnarsson K, Moshtaghi-Svensson J, Sysojev A\u00d6, Hesselstrand R, et al. Incidence, prevalence and mortality of systemic sclerosis in Italy: a nationwide population-based study using administrative health data. Rheumatol Int. 2020;41(1):129\u201337. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151978.","DOI":"10.1016\/j.semarthrit.2022.151978"},{"key":"3355_CR24","doi-asserted-by":"publisher","unstructured":"Ciaffi J, Morabito MF, Ruscitti P, D\u2019Angelo S, Mancarella L, Brusi V. Incidence, prevalence and mortality of systemic sclerosis in Italy: a nationwide population-based study using administrative health data. Rheumatol Int. 2020;41(1):129\u201337. https:\/\/doi.org\/10.1007\/s00296-020-04720-3","DOI":"10.1007\/s00296-020-04720-3"},{"issue":"2","key":"3355_CR25","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00296-016-3582-4","volume":"37","author":"R Foti","year":"2017","unstructured":"Foti R, Visalli E, Amato G. Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen. Rheumatol Int. 2017;37(2):245\u20139. https:\/\/doi.org\/10.1007\/s00296-016-3582-4.","journal-title":"Rheumatol Int"},{"issue":"1","key":"3355_CR26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1136\/ard.2006.066340","volume":"67","author":"L Czirj\u00e1k","year":"2008","unstructured":"Czirj\u00e1k L, Kum\u00e1novics G, Varj\u00fa C, Nagy Z, P\u00e1kozdi A, Szekanecz Z. Survival and causes of death in 366 Hungarian patients with systemic sclerosis. Ann Rheum Dis. 2008;67(1):59\u201363. https:\/\/doi.org\/10.1136\/ard.2006.066340.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"3355_CR27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.5301\/jsrd.5000209","volume":"1","author":"C Peoples","year":"2016","unstructured":"Peoples C, Medsger TA Jr, Lucas M, Rosario BL, Feghali-Bostwick CA. Gender differences in systemic sclerosis: relationship to clinical features, serologic status and outcomes. J Scleroderma Relat Disord. 2016;1(2):204\u201312. https:\/\/doi.org\/10.5301\/jsrd.5000209.","journal-title":"J Scleroderma Relat Disord"},{"issue":"1","key":"3355_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","volume":"58","author":"A Stochmal","year":"2020","unstructured":"Stochmal A, Czuwara J, Trojanowska M, Rudnicka L. Antinuclear antibodies in systemic sclerosis: an update. Clin Rev Allergy Immunol. 2020;58(1):40\u201351. https:\/\/doi.org\/10.1007\/s12016-018-8718-8.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"3355_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/anr.1780320109","volume":"32","author":"LJ McNeilage","year":"1989","unstructured":"McNeilage LJ, Youngchaiyud U, Whittingham S. Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum. 1989;32(1):54\u201360. https:\/\/doi.org\/10.1002\/anr.1780320109.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"3355_CR30","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1053\/sarh.2001.20268","volume":"30","author":"JD Reveille","year":"2001","unstructured":"Reveille JD, Fischbach M, McNearney T, Friedman AW, Aguilar MB, Lisse J. Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants. Semin Arthritis Rheum. 2001;30(5):332\u201346. https:\/\/doi.org\/10.1053\/sarh.2001.20268.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"3355_CR31","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s10067-011-1751-0","volume":"30","author":"ME Krzyszczak","year":"2011","unstructured":"Krzyszczak ME, Li Y, Ross SJ, Ceribelli A, Chan EKL, Bubb MR. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies. Clin Rheumatol. 2011;30(10):1333\u20139. https:\/\/doi.org\/10.1007\/s10067-011-1751-0.","journal-title":"Clin Rheumatol"},{"issue":"3","key":"3355_CR32","doi-asserted-by":"publisher","first-page":"994","DOI":"10.3892\/etm.2021.10426","volume":"22","author":"C Bobeica","year":"2021","unstructured":"Bobeica C, Niculet E, Halip AI. Predictive value of immunological markers in systemic sclerosis. Exp Ther Med. 2021;22(3):994. https:\/\/doi.org\/10.3892\/etm.2021.10426.","journal-title":"Exp Ther Med"},{"issue":"5","key":"3355_CR33","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.semarthrit.2004.08.004","volume":"34","author":"Y Alamanos","year":"2005","unstructured":"Alamanos Y, Tsifetaki N, Voulgari PV. Epidemiology of systemic sclerosis in northwest Greece 1981 to 2002. Semin Arthritis Rheum. 2005;34(5):714\u201320. https:\/\/doi.org\/10.1016\/j.semarthrit.2004.08.004.","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"3355_CR34","doi-asserted-by":"publisher","first-page":"e668","DOI":"10.1016\/s2665-9913(22)00193-x","volume":"4","author":"ER Volkmann","year":"2022","unstructured":"Volkmann ER, Tashkin DP, Silver R. Sex differences in clinical outcomes and biological profiles in systemic sclerosis-associated interstitial lung disease: a post-hoc analysis of two randomised controlled trials. Lancet Rheumatol. 2022;4(10):e668\u201378. https:\/\/doi.org\/10.1016\/s2665-9913(22)00193-x.","journal-title":"Lancet Rheumatol"},{"key":"3355_CR35","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13075-016-0933-1","volume":"18","author":"CR Pasarikovski","year":"2016","unstructured":"Pasarikovski CR, Granton JT, Roos AM. Sex disparities in systemic sclerosis-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther. 2016;18:30. https:\/\/doi.org\/10.1186\/s13075-016-0933-1.","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"3355_CR36","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1111\/nmo.12813","volume":"28","author":"JN Kimmel","year":"2016","unstructured":"Kimmel JN, Carlson DA, Hinchcliff M. The association between systemic sclerosis disease manifestations and esophageal high-resolution manometry parameters. Neurogastroenterol Motil. 2016;28(8):1157\u201365. https:\/\/doi.org\/10.1111\/nmo.12813.","journal-title":"Neurogastroenterol Motil"},{"issue":"3","key":"3355_CR37","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.reuma.2017.09.005","volume":"15","author":"AC Arana-Guajardo","year":"2019","unstructured":"Arana-Guajardo AC, Barrera-Torres G, Villarreal-Alarc\u00f3n M\u00c1, Vega-Morales D, Esquivel-Valerio JA. Esophageal symptoms and their lack of association with high-resolution manometry in systemic sclerosis patients. Reumatol Clin (Engl Ed). 2019;15(3):165\u20139. https:\/\/doi.org\/10.1016\/j.reuma.2017.09.005.","journal-title":"Reumatol Clin (Engl Ed)"},{"issue":"2","key":"3355_CR38","doi-asserted-by":"publisher","first-page":"R30","DOI":"10.1186\/ar2634","volume":"11","author":"N Hunzelmann","year":"2009","unstructured":"Hunzelmann N, Moinzadeh P, Genth E, Krieg T, Lehmacher W, Melchers I. High frequency of corticosteroid and immunosuppressive therapy in patients with systemic sclerosis despite limited evidence for efficacy. Arthritis Res Ther. 2009;11(2):R30. https:\/\/doi.org\/10.1186\/ar2634.","journal-title":"Arthritis Res Ther"},{"key":"3355_CR39","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac533","author":"M Iudici","year":"2022","unstructured":"Iudici M, Mongin D, Siegert E, Carreira P, Distler J, Henes J. Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database. Rheumatology (Oxford). 2022. https:\/\/doi.org\/10.1093\/rheumatology\/keac533.","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"3355_CR40","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327\u201339. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209909.","journal-title":"Ann Rheum Dis"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03355-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-024-03355-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-024-03355-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T10:05:34Z","timestamp":1727690734000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-024-03355-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3355"],"URL":"https:\/\/doi.org\/10.1186\/s13023-024-03355-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3268886\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"22 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Riga Stradins University medical ethics committee (Institutional Review Board reference no: 22\u2009\u2212\u20092\/481\/2021) and all participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"361"}}